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Abstract
Background: The house dust mite is the most important environmental allergen implicated in the
aetiology of childhood asthma in the UK. Dust mite barrier bedding is relatively inexpensive,
convenient to use, and of proven effectiveness in reducing mattress house dust mite load, but no
studies have evaluated its clinical effectiveness in the control of childhood asthma when dispensed
in primary care. We therefore aimed to evaluate the effectiveness of house dust mite barrier
bedding in children with asthma treated in primary care.
Methods: Pragmatic, randomised, double-blind, placebo controlled trial conducted in eight family
practices in England. Forty-seven children aged 5 to 14 years with confirmed house dust mite
sensitive asthma were randomised to receive six months treatment with either house dust mite
barrier or placebo bedding. Peak expiratory flow was the main outcome measure of interest;
secondary outcome measures included asthma symptom scores and asthma medication usage.
Results: No difference was noted in mean monthly peak expiratory flow, asthma symptom score,
medication usage or asthma consultations, between children who received active bedding and
those who received placebo bedding.
Conclusions: Treating house dust mite sensitive asthmatic children in primary care with house
dust mite barrier bedding for six months failed to improve peak expiratory flow. Results strongly
suggest that the intervention made no impact upon other clinical features of asthma.
Background
Asthma is now the commonest chronic disease of child-
hood in the UK and evidence strongly suggests recent in-
creases in prevalence and severity of the condition. [1–3]
Aetiologically, changes to the indoor environment have
been implicated in both these increases; proliferation in
British homes of soft furnishings, wall-to-wall carpets,
central heating, and double glazing, together with the ten-
dency for children to spend more time indoors, have all
combined to increase exposure to airborne indoor aller-
gens.[4] This pathophysiological element in the aetiology
of asthma is reflected in the current British Thoracic Soci-
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lergen avoidance should be considered in the treatment of
all patients with asthma.[5]
The allergen most commonly implicated in the UK is
house dust mite, mattresses, bedding, and carpets forming
its most important domestic reservoirs. A number of ap-
proaches to decreasing house dust mite exposure have
been tried, of which house dust mite impermeable bed-
ding is the most promising.[6] New semi-permeable (mi-
croporous) barrier bedding interventions are convenient
and offer several potential advantages including easy com-
pliance, a preventive approach to individual disease con-
trol and relatively low cost (Allerayde single bed set €153
+ VAT).
Though routine use of bedding interventions in dust mite
sensitive children with asthma is both logical and safe, un-
certainty remains about its clinical effectiveness.[7] The
majority of children with asthma are managed almost ex-
clusively in general practice, where the potential role of
barrier bedding is unknown. We sought to evaluate the ef-
fectiveness of semipermeable house dust mite barrier bed-
ding in children sensitised to the dust mite in a placebo
controlled trial conducted from primary care.
Methods
Study sample, inclusion and exclusion criteria
The study was conducted between 1998 and 1999 in eight
group practices recruited from the database of the Nation-
al Respiratory Training Centre. Practices satisfying the
study inclusion criteria were those that operated a dedicat-
ed nurse-led asthma clinic, and employed nurses who had
received formal training in asthma and allergy on courses
run by the National Asthma & Respiratory Training Cen-
tre. Ethical approval was obtained from the North London
Multi-centre and relevant Local Research Ethics Commit-
tees.
Parents of children aged 5–14 years with a recorded diag-
nosis of asthma and who had been prescribed one or
more asthma treatments in the preceding six months,
were contacted by telephone. Children with a clinical his-
tory suggestive of house dust mite allergy, as judged by a
positive response to the question 'has your child's asthma
ever got worse when the bed is made or when the vacuum-
ing or dusting is done?' were offered skin prick tests by
practice nurses. Prick tests were performed on the volar as-
pect of the forearm using standardised ALK Soluprik ex-
tracts of Dermatophagoides pteronyssinus (Der p1) and
using positive (histamine dihydrochloride) and negative
(allergen diluent) controls and were measured at 15 min-
utes. A positive response to Der p1 was defined as a weal
of at least five millimetres greater than that induced by the
negative control. Only children with both subjective and
objective evidence of allergy to the house dust mite were
invited to participate. Exclusion criteria were dermogra-
phism (because of the difficulty in interpreting skin prick
test results), children who did not use a duvet, those al-
ready using allergy control bedding, and cat or dog own-
ership. Pet owners were excluded because co-sensitivity in
dust mite sensitive individuals is common and the addi-
tional allergen load from the pet could swamp any effect
of the barrier bedding. Written consent from parents and
verbal consent from children aged seven and over was ob-
tained in all cases.
Randomisation and intervention
To eliminate possible allocation bias centralised randomi-
sation of individual patients was performed using num-
bers generated from a random numbers table. Bedding
sets comprising mattress, duvet and pillow covers were
posted from the randomisation centre directly to the
homes of recruited children. Bedding consisted of either
Allerayde Perfect house dust mite impermeable covers or
identical looking placebo covers produced by the same
company, and was supplied to patients in the study free of
charge, to be used for six months. Both subjects and nurs-
es were blinded to which trial arm children were allocated
to, as were those responsible for data analysis; the trial
code was broken after data analysis had been completed.
To ensure that only the effect of the bedding was being
evaluated all patients were given identical advice and writ-
ten instructions regarding ways to minimise house dust
mite exposure at home.
Parents were asked to keep a daily symptom diary for their
child detailing individual asthma (cough, wheeze, short-
ness of breath and chest tightness) and rhinitis (sneeze,
runny nose, blocked nose) symptoms on a four-point Lik-
ert scale (0–3). Each symptom score was tallied and
summed together to produce a 28-day composite score for
asthma, and for rhinitis. Such symptom scores could vary
between 0 (no symptoms) and 336 for asthma, between 0
(no symptoms) and 252 for rhinitis. Details of daily usage
of asthma medication and episodes of night-time waking
were also recorded.
Each practice nurse reviewed children at monthly intervals
for six months, measured peak expiratory flow (recording
the best reading from three attempts), assessed asthma
control, and asked parents whether the bedding covers is-
sued were still being used. At the two-month post-inter-
vention assessment, and thereafter, patients whose
asthma control was considered good by the nurses were
advised to reduce inhaled steroid use by 50%, in the con-
text of clear instructions regarding steps to be taken
should asthma symptoms deteriorate. In the event of
acute exacerbations of asthma nurses recommended a
standardised protocol regarding indications for use of oralPage 2 of 6
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general practitioner.
The initial assessment, involving skin prick testing, was
performed in the patient's home. Thereafter, children
were seen at monthly intervals in the practice asthma clin-
ic until the final assessment, which was performed at the
child's home. On completing the study, nurses checked
paper and electronic medical records to extract data on all
non-study related practice consultations, and accident &
emergency department consultations for asthma, hospital
admissions for asthma, and details of the number of
courses of oral steroids prescribed during the study peri-
od.
Statistical methods
To detect an average within person change of 10% or
more in peak expiratory flow (PEF) from baseline reading
at the start of the study with 80% power at the 5% signif-
icance level (assuming a within person standard deviation
of 35 l/min), we estimated that 21 patients were needed
in each arm of the study. Normally distributed data were
analysed using student t-test and mean values and stand-
ard deviations calculated; the Mann Whitney test was used
for non-parametric data and medians and inter-quartile
ranges calculated. Categorical data were analysed using
Chi-square test or Fisher's exact test in the event of small




The combined list size of study practices was 55,687, of
whom 6095 patients were aged 5–14 years of whom 1157
(19%) had a recorded diagnosis of asthma. Four hundred
and seventy two children were approached to join the
study 47 of whom satisfied the inclusion criteria. Reasons
for excluding patients are summarised in Table 1.
Forty-three children (92%) completed the study (Figure
1), all of whom reported use of bed covers supplied for the
duration of the trial. Three of the children lost to follow-
up failed to attend for scheduled reviews; parents of the
fourth child stated they no longer wished to participate.
Mean age of children was 11.0 years (sd 2.26) with a pre-
ponderance of boys (62%). The treatment arm contained
26 (55%) children and the placebo group 21 (45%). De-
tails of age, sex, baseline asthma symptom scores, medica-
tion usage, and peak expiratory flow measures for each
group are given in Table 2. There was no major difference
between groups in baseline skin prick test weal diameter
to house dust mite, or in the proportion of households
with a smoker, bedroom central heating, double-glazing
or wall-to-wall carpets.
Peak expiratory flow, symptom scores, and health care uti-
lisation
Comparisons of changes in peak expiratory flow and oth-
er clinical data are summarised in Table 3. The results
show that whilst mean peak expiratory flow increased in
both groups when compared to baseline, there was no sig-
nificant difference in the increases achieved when com-
paring active and placebo treated groups. Although mean
asthma, rhinitis and night-time waking scores decreased
from baseline in both groups, differences were not signif-
icant when comparing placebo and active treatment arms.
Of interest is that these tendencies towards improvement
in symptomatic and clinical outcomes, when compared to
baseline, were seen in the context of reductions in mean
inhaled corticosteroid usage when compared with base-
line usage. Only four children (two in each arm) required
courses of oral steroid throughout the study and there
were no asthma-related hospital admissions during this
time period.
Discussion
In a carefully selected population of HDM sensitive chil-
dren 6 months community based treatment with allergy
control bedding achieved no significant improvement in
peak expiratory flow in those treated with impermeable
bedding covers compared with those treated with placebo
covers. The trial results also suggest that HDM impermea-
ble covers made no impact on other clinical features of
asthma. The trial was sufficiently powered to detect a clin-
ically significant improvement for our main outcome
measure of interest, peak expiratory flow, but this is not
true of the other outcome measures studied. One possible
reason for the lack of effect is that families did not comply
with the intervention. Although we did not measure com-
pliance directly, self-reported compliance was very good,
and nurses did not report any lack of bedding usage in
home assessments undertaken at the end of the study
when each child's bed was inspected to see if the covers
were still in place. Another possible explanation for the
Table 1: Reasons for excluding children
Reason for exclusion n (%)
Lack of parental interest 123 (29)
Pet ownership 106 (25)
No asthma medication in previous 6 months 89 (21)
Skin prick test <5 mm to house dust mite 64 (15)
Already using allergy control bedding 17 (4)
Child not using a duvet 9 (2)
Child not sleeping in own bed 4 (1)
Unrecorded 13 (3)
Total 425Page 3 of 6
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failed to reduce house dust mite load sufficiently. Due to
an ambiguity in the sampling protocol, we were unable,
in this study, to obtain valid information on post-inter-
vention house dust mite loads, but data from other stud-
ies show bedding covers of the sort we supplied to be
highly effective in reducing mattress dust mite load.[8] A
further possible explanation could be that the patients re-
cruited on average suffered relatively mild disease (reflect-
ed by their low baseline asthma symptom scores); they
were therefore sufficiently well controlled on existing
treatment for little scope to remain for clinical improve-
ment (Table 2).
The majority of asthmatic children managed in primary
care have mild to moderate disease; in an attempt to max-
imise the chances of detecting clinical improvement we
only recruited children who had active asthma (as evi-
denced by recent prescription for asthma medication) in
whom attempts were made to reduce inhaled steroid use
in a standardised manner. We used PEF as our primary
outcome measure of interest since this is the objective
measure most commonly used by general practitioners
and paediatricians; spirometry would not have been feasi-
ble in such young children. Because of concerns regarding
the validity of self-recorded PEF in children, however, we
opted for nurse-supervised clinic based recording rather
than early morning PEF, another possible explanation for
our failure to detect a difference. Finally, there is the pos-
sibility that the intervention reduced dust mite load but
this failed to produce measurable clinical impact on pa-
tients.[9]
Allergen avoidance measures are likely to be of most ben-
efit in patients truly sensitive to the allergen in question.
We therefore only included children with unequivocal al-
lergy to the house dust mite as determined by both a sub-
jective clinical history and objective positive weal and
flare response on skin prick testing. Our findings suggest
firstly that allergy to this organism, defined by a positive
Table 2: Baseline comparison between treatment and placebo groups
Variable HDM impermeable bedding, n = 26 Placebo bedding, n = 21
Age, mean (sd) 10.58 (2.34) 11.57 (2.08)
Males (%) 16 (62) 13 (62)
Peak expiratory flow in litres/min, mean (sd) 288.80 (100.80) 328.57 (73.02)
Number on inhaled steroids (%) 5 (19.2) 5 (23.8)
28-day asthma symptom score (0–336), median (inter-qaurtile range) 12.0 (6.5 to 52.5) 37.0 (9.0 to 69.0)
28-day rhinitis symptom score (0–252), median (inter-quartile range) 50.5 (19.8 to 82.5) 51.0 (23.5 to 84.5)
Episodes of night-time waking over 28 days, median (inter-quartile range) 0 (0 to 0.75) 0 (0 to 3.0)
28-day dose inhaled steroid mcg/month, median (inter-quartile range) 5600 (1450 to 11,100) 5400 (58 to 11,200)
28-day dose bronchodilator mcg/month, median (inter-quartile range) 800 (125 to 1700) 400 (100 to 42)
Table 3: Comparison of changes from beginning to end of study in clinical outcomes between treatment and placebo groups
Medical outcome variable HDM Impermea-
ble bedding, n = 23
Placebo bedding, 
n = 20
95% CI of differ-
ence
Significance p
Mean change in 28-day PEF litres/min (sd) 16.38 (25.62) 13.68 (43.14) -25.15 to 19.75 0.81
Mean change in 28-day asthma symptom scores (sd) -3.40 (29.50) -18.10 (27.80) -33.16 to 3.86 0.12
Mean change in 28-day rhinitis symptom scores (sd) -31.14 (35.79) -22.67 (30.70) -13.15 to 30.09 0.43
Mean change in episodes of monthly night-time waking over 
28-day period (sd)
-0.64 (3.00) -0.94 (2.30) -2.05 to 1.93 0,43
Mean change in 28-day dose of inhaled steroids mcg (sd) -1815.91 (3861.45) -1039.00 (1881.15) -1128.58 to 
2682.59
0.41
Median non-study GP consultations (range) 1 (0–5) 0 (0–5) 0.26
Total number of hospital admissions for asthma 0 0 1
Total number of courses of oral steroids for asthma 2 2 1Page 4 of 6
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Number receiving treatment bedding
n=26
Number receiving placebo bedding
n=21
Number who did not reach primary endpoint
n=1
Number who did not reach primary endpoint
n=3
Number analysed for primary endpoint
n=20
Number analysed for primary endpoint
n=23Page 5 of 6
(page number not for citation purposes)
BMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/12history and skin prick test of five millimetres or more, may
not be as prevalent in GP registered populations as previ-
ously suspected. Clinical history alone appears to have
low predictive value for allergy to dust mite in asthmatic
children,[10] and house dust mite barrier bedding has at
most only a minor impact on health outcomes for chil-
dren with mild asthma in non pet owning families man-
aged in general practice.
The rationale for offering patients advice in general prac-
tice about house dust mite avoidance for asthma (or for
other house dust mite associated conditions such as per-
ennial rhinitis) requires recourse to objective tests such as
skin prick testing. Very few general practitioners currently
perform skin prick testing, lacking both the training and
financial support to do so.[11] The alternative of radio-al-
lergo absorbent testing (RAST) is more expensive.
Our study adds support to the conclusions of a recent
meta-analysis of house dust mite avoidance measures in
asthma patients, which concluded that existing interven-
tions designed to decrease domestic dust mite exposure
are of little, if any, clinical benefit.[12] Our results, in con-
junction with those of the meta-analysis, lead us to ques-
tion whether routine use of house dust mite barrier
bedding as treatment for mildly affected asthmatic chil-
dren can be justified in the clinical setting of general prac-
tice. Further explanatory and pragmatic intervention
studies are required, to estimate the value, if any, of mite
reduction strategies in mite sensitive asthmatic children
with more severe disease.
Conclusions
In a carefully selected population of HDM sensitive chil-
dren, 6 months community based treatment with allergy
control bedding achieved no significant improvement in
peak expiratory flow in those treated with impermeable
bedding covers compared with those treated with placebo
covers. Until the results of other trials evaluating the role
of house dust mite barrier bedding become available, we
recommend that topical corticosteroids remain the treat-
ment of choice in those children with persistent asthma
symptoms.
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